CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Revenues
Total revenues	$ 18,168,677	$ 9,027,738
Total cost of revenues	13,115,037	4,544,832
Gross profit	5,053,640	4,482,906
Operating expenses:
Selling, general and administrative	15,097,360	12,845,372
Research and development	3,926,043	4,164,434
Impairment losses	0	821,741
Total operating expenses	19,023,403	17,831,547
LOSS FROM OPERATIONS	(13,969,763)	(13,348,641)
Other (expense) income:
Interest income, net	7,200	13,675
Loss on extinguishment of convertible notes payable	0	(1,774,662)
Unrealized gain on change in fair value of warrants classified as a liability	17,999,521	0
Gain on extinguishment of notes payable	0	839,945
Transaction costs related to warrant liabilities	(1,668,112)
Loss on issuance of warrants	(10,591,600)	0
Other expense, net	(47,305)	(8,756)
Loss before provision for income taxes	(8,270,059)	(14,278,439)
Provision for income taxes	0	0
NET LOSS	(8,270,059)	(14,278,439)
Less: Net (income) loss attributable to noncontrolling interest	2,168	(8,003)
NET LOSS attributable to Applied DNA Sciences, Inc.	(8,267,891)	(14,286,442)
Deemed dividend related to warrant modifications	110,105
NET LOSS attributable to common stockholders	$ (8,377,996)	$ (14,286,442)
Net loss per share attributable to common stockholders - basic	$ (0.93)	$ (2.07)
Net loss per share attributable to common stockholders - diluted	$ (0.93)	$ (2.07)
Weighted average shares outstanding - basic	8,967,704	6,916,999
Weighted average shares outstanding - diluted	8,967,704	6,916,999
Product revenues
Revenues
Total revenues	$ 1,882,804	$ 3,295,849
Total cost of revenues	2,116,717	1,566,656
Service revenues
Revenues
Total revenues	759,138	937,735
Clinical laboratory service revenues
Revenues
Total revenues	15,526,735	4,794,154
Total cost of revenues	$ 10,998,320	$ 2,978,176